Cyclerion Therapeutics, Inc. (CYCN)
NASDAQ$2.55+0.02 (0.79%)
Market Cap
$6.86M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
546 of 924
Rank in Industry
319 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
CYCN Insider Trading Activity
CYCN Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $555,108 | 1 | 100 |
Related Transactions
| Slate Path Capital LP | 10 percent owner | 0 | $0 | 1 | $555,108 | $-555,108 |
About Cyclerion Therapeutics, Inc.
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also …
Insider Activity of Cyclerion Therapeutics, Inc.
Over the last 12 months, insiders at Cyclerion Therapeutics, Inc. have bought $0 and sold $555,108 worth of Cyclerion Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Cyclerion Therapeutics, Inc. have bought $4.37M and sold $214,373 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 961,538 shares for transaction amount of $3M was made by Slate Path Capital LP (10 percent owner) on 2021‑06‑03.
List of Insider Buy and Sell Transactions, Cyclerion Therapeutics, Inc.
| 2024-11-21 | Sale | Slate Path Capital LP | 10 percent owner | 357,880 11.132% | $1.55 | $555,108 | +111.97% | |
| 2023-08-09 | Sale | MCGUIRE TERRANCE | director | 8 0.0003% | $3.40 | $27 | -10.40% | |
| 2021-06-03 | Slate Path Capital LP | 10 percent owner | 961,538 0.1301% | $3.12 | $3M | -39.01% | ||
| 2021-06-03 | Hecht Peter M | Chief Executive Officer | 823,170 0.1171% | $3.28 | $2.7M | -39.01% | ||
| 2021-06-03 | MCGUIRE TERRANCE | director | 96,153 0.013% | $3.12 | $299,997 | -39.01% | ||
| 2021-05-06 | Hecht Peter M | Chief Executive Officer | 302,000 0.0413% | $2.43 | $733,860 | +6.43% | ||
| 2021-05-05 | Hecht Peter M | Chief Executive Officer | 398,001 0.0553% | $2.53 | $1.01M | +3.92% | ||
| 2021-05-04 | Hecht Peter M | Chief Executive Officer | 300,000 0.0415% | $2.29 | $687,000 | +14.22% | ||
| 2021-02-25 | Sale | Wright Christopher I | Chief Medical Officer | 2,637 0.0004% | $3.99 | $10,522 | -24.61% | |
| 2021-02-25 | Sale | Gjino Anjeza | Chief Financial Officer | 1,824 0.0003% | $4.00 | $7,296 | -24.61% | |
| 2020-12-28 | Sale | Currie Mark G | President and CSO | 20,107 0.0032% | $3.01 | $60,522 | +3.68% | |
| 2020-11-09 | Busch Andreas | Chief Innovation Officer | 125,000 0.0199% | $2.53 | $316,250 | +27.42% | ||
| 2020-11-06 | Sale | Huyett William | Chief Financial Officer | 3,827 0.0006% | $2.52 | $9,644 | +27.42% | |
| 2020-02-21 | Sale | Huyett William | Chief Financial Officer | 3,559 0.0007% | $5.12 | $18,222 | -16.49% | |
| 2019-12-30 | Sale | Currie Mark G | President | 25,000 0.0839% | $2.48 | $62,000 | +42.59% | |
| 2019-12-27 | Sale | Currie Mark G | President | 25,000 0.0917% | $2.55 | $63,750 | +51.97% | |
| 2019-11-15 | Busch Andreas | Chief Innovation Officer | 125,000 0.4616% | $1.82 | $227,500 | +114.44% | ||
| 2019-11-08 | Sale | Huyett William | Chief Financial Officer | 3,922 0.0155% | $2.05 | $8,040 | +103.16% | |
| 2019-04-08 | SCHULMAN AMY W | director | 626,117 0.1105% | $16.00 | $10.02M | -46.83% | ||
| 2019-04-08 | MCGUIRE TERRANCE | director | 626,117 0.1105% | $16.00 | $10.02M | -46.83% |
Total: 21
*Gray background shows transactions not older than one year
Insider Historical Profitability
6.18%
| Slate Path Capital LP | 10 percent owner | 0 0% | $0 | 1 | 1 | <0.0001% |
| Hecht Peter M | Chief Executive Officer | 2047698 75.558% | $5.18M | 4 | 0 | <0.0001% |
| SCHULMAN AMY W | director | 604482 22.3048% | $1.53M | 1 | 0 | |
| Busch Andreas | Chief Innovation Officer | 254704 9.3983% | $644,401.12 | 2 | 0 | +70.93% |
| Currie Mark G | President and CSO | 251648 9.2856% | $636,669.44 | 1 | 3 |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$1,226,605 | 43 | -21.28% | $7.98M | |
$523,320 | 24 | 94.37% | $7.01M | |
$746,223 | 23 | -7.24% | $9.07M | |
$31,129 | 22 | -11.96% | $6.19M | |
$1,080,165 | 17 | -6.62% | $7.91M |
CYCN Institutional Investors: Active Positions
| Increased Positions | 7 | +38.89% | 21,632 | +2.07% |
| Decreased Positions | 5 | -27.78% | 682,328 | -65.44% |
| New Positions | 5 | New | 10,747 | New |
| Sold Out Positions | 2 | Sold Out | 527,340 | Sold Out |
| Total Postitions | 20 | +11.11% | 381,943 | -63.37% |
CYCN Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Tyndall Capital Partners L P | $417.00 | 5.49% | 164,777 | 0 | 0% | 2024-12-31 |
| Siren, L.L.C. | $294.00 | 3.87% | 116,155 | 0 | 0% | 2024-12-31 |
| Geode Capital Management, Llc | $81.00 | 1.06% | 31,820 | -2,088 | -6.16% | 2024-12-31 |
| Vanguard Group Inc | $59.00 | 0.78% | 23,490 | 0 | 0% | 2024-12-31 |
| Blackrock, Inc. | $42.00 | 0.56% | 16,797 | 0 | 0% | 2024-12-31 |
| Renaissance Technologies Llc | $27.00 | 0.35% | 10,611 | +10,611 | New | 2024-12-31 |
| Ubs Group Ag | $24.00 | 0.32% | 9,667 | +9,522 | +6,566.9% | 2024-12-31 |
| Fmr Llc | $12.00 | 0.16% | 4,740 | -152,896 | -96.99% | 2024-12-31 |
| Tower Research Capital Llc (Trc) | $6.00 | 0.08% | 2,441 | +1,363 | +126.44% | 2024-12-31 |
| Morgan Stanley | $2.00 | 0.02% | 649 | 0 | 0% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
No data is available at this moment.
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.